AFFERENT PHARMACEUTICALS
Afferent Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical company. It develops medicines to treat chronic pain by targeting P2X3 receptors in nerve fibers. The company’s AF-219, a compound that completed two Phase 1 clinical studies. Afferent Pharmaceuticals, Inc. was founded in 2009 and is based in San Mateo, California.
AFFERENT PHARMACEUTICALS
Social Links:
Industry:
Biopharma Biotechnology Pharmaceutical
Founded:
2009-01-01
Address:
San Mateo, California, United States
Country:
United States
Website Url:
http://www.afferentpharma.com
Total Employee:
11+
Status:
Closed
Contact:
(650) 286-1276
Email Addresses:
[email protected]
Total Funding:
83.15 M USD
Technology used in webpage:
SPF Google Font API Google Maps Amazon Microsoft Exchange Online GStatic Google Static Content Google Maps API Microsoft Azure DNS AWS Global Accelerator MediaElement.js
Similar Organizations
Aimmune Therapeutics
Aimmune Therapeutics is a clinical-stage biopharmaceutical company that improves the lives of people with food allergies.
Celator Pharmaceuticals
Celator Pharmaceuticals is a biopharmaceutical company developing therapies to treat cancer, using the drug ratio technology platform.
Corvus Pharmaceuticals
Corvus Pharmaceuticals is a clinical-stage biopharmaceutical company.
Edgewise Therapeutics
Edgewise Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization.
Eidos Therapeutics
Eidos Therapeutics is a clinical-stage biotech company developing novel, genetically targeted therapies to improve the lives of patients.
PhaseBio Pharmaceuticals
PhaseBio is a clinical-stage biopharmaceutical company that develops drugs for cardiovascular diseases, endocrine, and metabolic disorders.
Proteostasis Therapeutics
Proteostasis Therapeutics is a clinical stage biopharmaceutical company developing small molecule therapeutics to treat cystic fibrosis.
Reata Pharmaceuticals
Reata Pharmaceuticals is a biopharmaceutical company that develops drugs for cancer, inflammation, and neurodegenerative diseases.
Reviva Pharmaceuticals
Reviva Pharmaceuticals is a clinical-stage pharmaceutical company developing innovative therapies.
Sparrow Pharmaceuticals
Sparrow Pharmaceuticals is a clinical-stage biopharmaceutical company developing treatments for disorders of corticosteroid excess.
Current Advisors List
Founder
Investors List
Fidelity
Fidelity investment in Series C - Afferent Pharmaceuticals
Partner Fund Management
Partner Fund Management investment in Series C - Afferent Pharmaceuticals
New Leaf Venture Partners
New Leaf Venture Partners investment in Series C - Afferent Pharmaceuticals
Jennison Associates
Jennison Associates investment in Series C - Afferent Pharmaceuticals
Redmile Group
Redmile Group investment in Series C - Afferent Pharmaceuticals
Tekla Capital Management
Tekla Capital Management investment in Series C - Afferent Pharmaceuticals
Domain Associates
Domain Associates investment in Series B - Afferent Pharmaceuticals
Third Rock Ventures
Third Rock Ventures investment in Series B - Afferent Pharmaceuticals
Pappas Ventures
Pappas Ventures investment in Series B - Afferent Pharmaceuticals
Third Rock Ventures
Third Rock Ventures investment in Series A - Afferent Pharmaceuticals
Official Site Inspections
http://www.afferentpharma.com
- Host name: ab2ca2ac67592bd12.awsglobalaccelerator.com
- IP address: 13.248.206.15
- Location: Seattle United States
- Latitude: 47.6348
- Longitude: -122.3451
- Metro Code: 819
- Timezone: America/Los_Angeles
- Postal: 98109
More informations about "Afferent Pharmaceuticals"
Afferent Pharmaceuticals - Crunchbase Company …
Organization. Afferent Pharmaceuticals . Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News. Similar Companies. ... Contact Email [email protected]; Phone Number (650) 286-1276; Afferent …See details»
Afferent Pharmaceuticals Company Profile | Management and
Www.afferentpharma.com . Afferent Pharmaceuticals Profile and History. Afferent Pharmaceuticals is a clinical-stage biotechnology company and a leader in the development of …See details»
Afferent Pharmaceuticals - Products, Competitors, Financials, …
Headquarters Location. 2929 Campus Drive Suite 230. San Mateo, California, 94403, United States. 650-286-1276See details»
Merck to Acquire Afferent Pharmaceuticals
Jun 9, 2016 Merck (NYSE:MRK), known as MSD outside the United States and Canada, and Afferent Pharmaceuticals announced today that the two companies have signed a definitive agreement under which Merck will acquire this …See details»
Afferent Pharmaceuticals - Overview, News & Similar companies ...
Afferent Pharmaceuticals contact info: Phone number: (650) 286-1276 Website: www.afferentpharma.com What does Afferent Pharmaceuticals do? Afferent Pharmaceuticals …See details»
Afferent Pharmaceuticals - PitchBook
Afferent Pharmaceuticals General Information Description. Developer of drugs for the treatment of neurogenic disorders. The company develops small molecule compounds that target P2X3 receptors for the treatment of chronic pain, …See details»
Merck to Acquire Biotech Company Afferent …
For more information on the company, please visit Afferent’s website at www.afferentpharma.com. About Merck For 125 years, Merck has been a global health care leader working to help the world be well. Merck is known as MSD …See details»
Afferent Pharmaceuticals - Pappas Capital
Pappas Ventures co-founded Afferent in December 2009, after recognizing a novel mechanism with high potential in the treatment of chronic pain and other areas of substantial medical need.See details»
Merck to buy biotech drug developer Afferent Pharmaceuticals
Jun 9, 2016 KENILWORTH, N.J. (AP) — Drugmaker Merck is buying Afferent Pharmaceuticals, a privately held biotechnology company developing a chronic cough medication. Merck & Co., …See details»
Merck signs definitive agreement to buy US firm …
Jun 9, 2016 Given the background of high inflation, re-emerging supply chain issues, and the widespread macro-economic implications of the Ukraine conflict, the global pharmaceutical industry is facing an entirely new set of challenges …See details»
Merck (MRK) to Acquire Afferent in Deal Worth Up To $1.25B
Jun 10, 2016 Merck & Co. Inc. MRK announced its intention to acquire privately held biotech company Afferent Pharmaceuticals in a deal which could see the company paying up to $1.25 …See details»
Anthony P. Ford - Chief Executive Officer - Crunchbase
Dr. Ford is co-founder and chief scientific officer of Afferent. An accomplished pharmacologist and former vice president of research at Roche, Dr. Ford initiated and drove the P2X3 program at …See details»
Afferent Pharmaceuticals - CB Insights
Explore {Afferent Pharmaceuticals's key management people. Discover current leadership team members including founders, CEO, other executives and board directors.See details»
Merck & Co. to Acquire Afferent Pharmaceuticals for Up to $1.25B
Jun 10, 2016 Merck & Co. will acquire Afferent Pharmaceuticals for up to $1.25 billion, the companies said today, in a deal that expands the pharma giant’s pipeline with candidates for …See details»
Merck buys cough drug developer Afferent for $1.25bn - PMLiVE
Jun 10, 2016 Merck & Co has agreed a deal to buy California biopharma company Afferent Pharma, adding a drug candidate for chronic cough to its pipeline. The deal – which includes …See details»
Afferent Pharmaceuticals Names Bruce G. McCarthy, M.D., as CEO
Jan 26, 2010 Additional information regarding Afferent can be found on the company's website at www.afferentpharma.com. Contacts Pure Communications, Inc. Sheryl Seapy, 949-608 …See details»
Merck to Acquire Afferent Pharmaceuticals - Business Wire
Jun 9, 2016 For more information on the company, please visit Afferent’s website at www.afferentpharma.com. About Merck For 125 years, Merck has been a global health care …See details»
Roche Licenses First-in-Class Treatments for Chronic Pain to …
Dec 16, 2009 About Afferent. Afferent Pharmaceuticals is focused on developing first-in-class medicines to treat chronic pain by targeting P2X3 receptors in nerve fibers.See details»
P2X3 Antagonists: Novel Therapeutics for Afferent Sensitization …
Financial & competing interests disclosure. AP Ford is scientific founder and a paid employee of Afferent Pharmaceuticals. The author has no other relevant affiliations or financial involvement …See details»
Afferent Pharmaceuticals Presents Updated Positive ... - Business …
May 16, 2016 Afferent Pharmaceuticals Dulce Dizon, 650-286-1276 [email protected] or Media: Kinkead Communications, Inc. Susan Kinkead, 415-509-3610 …See details»